Sosei appoints Peter Bains as COO and President elect

He is expected to become Representative Executive Officer, President and Chief Executive at the AGM in June

Japanese biopharmaceutical firm Sosei Group will have a new Chief Operating Officer (COO) from 1 April.

From next week, Peter Bains will assume responsibility for all operational activities of Sosei and will report to Shinichi Tamura in his ongoing capacity as Group Chairman, President and Chief Executive Officer (CEO). It is expected that Bains will become Representative Executive Officer, President and Chief Executive Officer (CEO) upon approval by the Board of Directors following Sosei Group’s Annual General Meeting in June. At the same time, Tamura is expected to become Representative Executive Officer and Executive Chairman.

Bains has nearly 30 years of experience in the pharmaceutical industry encompassing strategic and operational leadership expertise across global geographies, functions and business segments. He had a 23-year career at GlaxoSmithKline, where he held multiple senior roles including General Manager of China, VP of International Business Development, Head of Global Marketing and Senior VP of International Commercial Development.

Since 2009, he has been a consultant specialising in supporting strategic growth opportunities in small- and medium-sized innovation-based life science companies. He currently serves as an Non-executive Director at Sosei Group, and as CEO at Syngene, a subsidiary of biotechnology company Biocon.

Bains said: 'Sosei Group is now at a very dynamic point in its history as it seeks to expand its operational scope and scale, and I am looking forward to contributing to its rapid evolution into a truly global biopharmaceutical company.'

You may also like

Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Packaging

Dual-chamber packaging systems as a simplification factor in the supply chain

Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
Regulatory

Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi

The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
Subscribe now